Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPI-121 0.25% in Dry Eye Disease (STRIDE 3)
NCT03616899Phase 3Completed
- Sponsor
- KALA BIO
- Start
- Jul 2018
- Primary completion
- Feb 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of loteprednol etabonate ophthalmic gel 0.38% in dry eye disease (DED), sponsored by KALA BIO. Started Jul 2018; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT03616899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616899.